A 2018 study conducted by Mo et al. using IFN-α for the treatment for MRD in AML for example, reported that all patients reported transient fevers and six patients (14%) showed grade ≥3 toxicity, two of which were haematological (77). This evidence concerns the gene IFNA1 and acute myeloid leukemia.